Autres langues Gilead Sciences, Inc.

Actions

GILD

US3755581036

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
150,93 ^USD	+0,83 %		+0,55 %	+22,97 %

25/09	ACTUALITÉS MÉDICALES – Une découverte génétique ouvre des pistes pour inverser les lésions cérébrales liées à la maladie d’Alzheimer	RE
18/09	Dr. Reddy's confirme l'obtention d'une licence pour le traitement annuel contre le VIH de Gilead ; l'action grimpe de 2%	MT

Autres langues

25/09	HEALTH ROUNDS-Genetic discovery yields clues toward reversal of Alzheimer's brain damage
18/09	Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
18/09	Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2%
16/09	Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing
16/09	Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited
16/09	Gilead Sciences Expands Licensing Agreements for HIV Treatment
16/09	Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
15/09	Gilead Sciences, Inc. and Pan American Health Organization Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
15/09	Gilead Sciences Expands Lenacapavir Access to 14 Countries
15/09	Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean
15/09	Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
08/09	Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead
08/09	Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead
08/09	Assembly Biosciences, Inc. and Gilead Sciences, Inc. Exercise U.S. Profit-Share Option for HSV Helicase-Primase Inhibitor Program
08/09	Gilead Sciences Opens Research Center At Foster City Headquarters
08/09	Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
07/09	Gilead Sciences Announces FDA Approval for Bixlenvo as A Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv
03/09	AbbVie's blood cancer therapy lowers disease progression, death risk in trial
01/09	Global pharma companies that have publicly announced Trump drug pricing agreements
28/08	Afternoon Meeting: Warsh entra en escena
28/08	Warsh Takes the Stage
28/08	Morning Meeting: Zwei Märkte, zwei Geschichten
28/08	A tale of two markets
28/08	Gilead Sciences : Breaks Ground on New Biologics Facility as Part of $32 Billion U.S. R&D and Manufacturing Investment
28/08	Gilead Sciences Wins FDA Approval for HIV Pill Bixlenvo